Clinresco Centres has performed clinical studies in the following therapeutic areas:

  • Ankylosing spondylitis
  • Atrial fibrillation
  • Cardiovascular diseases (including heart attacks and strokes)
  • Chronic heart failure
  • Chronic obstructive pulmonary disease
  • Diabetes Mellitus (Type II)
  • Hyperlipidaemia
  • Hypertension
  • Gout
  • Infections
  • Influenza
  • Osteoarthritis
  • Osteoporosis
  • Pain management
  • Prostate cancer
  • Psoriatic arthritis
  • Rheumatoid arthritis
  • Thrombotic events

Partner site:

Clinresco Centres is a partner site of Quintiles since February 2009. The goal of this relationship is to improve access to investigative site’s medical staff and patient population, improving access to patients and timely recruitment in clinical trials.

A recent analysis of performance done on 21 Quintiles managed studies showed that Clinresco recruited nearly double the number of patients in half the time of an average site involved with studies at Quintiles.

Quintiles also assists the site in maintaining a consistently high standard for the conduct of clinical trials. Additional information is available at the following link:

“Inspire” site:

In 2013 Clinresco was identified by Pfizer, the largest pharmaceutical company in the world, as a site that meets the exacting standards that the company demands to join a worldwide network of 150 INSPIRE sites, which must be both highly productive and effective.

INSPIRE, which is the acronym for Investigator Networks, Site Partnerships and Infrastructure for Research Excellence, means that these sites have early access to Pfizer’s portfolio data and advanced information regarding the clinical trials to be sponsored by Pfizer. Clinresco is looking forward to joining hands with this global network of clinical research institutions.

Training of World Health Organisation (WHO) auditors:

On behalf of the World Health Organisation (WHO) the South African Medicines Control Council (MCC), from time to time, trains GCP auditors from African States.  In 2013 Clinresco was selected for the purpose of assisting with a one day mock inspection as part of the training of 14 clinical trial inspector trainees. The successful training, lead by a member of the regulatory authority (MCC), was done on a paper based clinical report form (CRF) study with input from Clinresco personnel. The required physical facilities and sysytems for conducting approved clinical trials was explained and viewed in detail.
– credentials